Increase Cell Performance with Recombinant Human Albumin

How recombinant human albumin can increase cell viability and provide consistent performance

As a long-established ingredient of cell-culture media, albumin is well recognized for its ability to facilitate growth of many cell types. The industry is now seeing its properties expanded for use in the cryopreservation and formulation of stem cell therapies. As part of this webinar we look at the manufacturing, formulation and logistic challenges associated with the development of cell therapies and assesses how the use of fully recombinant human albumin in especially the cryopreservation of stem cells is demonstrating new potential for the regenerative medicine field.

The advance of stem cell therapies presents several development and formulation challenges. Product heterogeneity is one of the main concerns and is a function of the entire value chain design, from harvesting, upstream culture and cell preservation, to cell therapy administration. Consequently, pharmaceutical companies are striving to understand and control all steps in order to increase cell viability and minimize variability.

This webinar will discuss the use of recombinant human albumin in stem and immune cell therapies, with the following focus:

• Primary challenges faced by the cell therapy industry today
• Albumin in cell therapies: Properties of albumin and areas of application in cell therapy
• Recombinant albumin: What are the benefits of choosing a recombinant product
• Increasing cell viability during cryopreservation
• Use of albumin in isolating lymphocytes

Stem cell therapy is a cutting-edge therapeutic field, but still young and with a lot of room for optimization to ensure they reach patients. Recombinant human albumin offers a safe solution for optimized cell performance. As an animal and human component free product it provides regulatory benefits while improving cell viability and controlling batch-to-batch consistency. In this webinar, we will share examples of how using a ultra-pure recombinant human albumin source in the down-stream processing of cell therapies offers advantages along the entire value chain.

Solving the processing and formulation challenges in the field of cell therapies is a daunting task; listen in on this webinar to learn more about how the use of recombinant human albumin may provide some of the answers and give you confidence in your cell therapy development.

Presented by

Joaquim Vives, Head of Laboratory for the Development of Cell Therapies

Joaquim Vives is a Biochemist, MSci in Biotechnology and PhD in Biochemistry with extensive experience in the R&D biotech sector, both in private and academic environments, where he focused on the optimization of cellular processes towards A) high yield production of diagnostic and therapeutic molecules, and B) the development of methods to produce cells for drug screening and as a therapy, in compliance with current regulatory and quality standards.

Dr. Vives conducted post-doctoral research at the Institute for Stem Cell Research (University of Edinburgh, UK), then moved to Stem Cell Sciences Ltd (Cambridge, UK), and joined Banc de Sang i Teixits (Barcelona, Spain), where he currently leads the Laboratory for the Development of Cell Therapies.

Phil Morton, Science Director

Phil Morton is a Science Director heading up the Bioprocess Characterization function within Albumedix R&D. He has 20+ years' experience in the biopharmaceutical industry within process and product development.

His experience ranges from developing and transferring purification processes, to formulation development and characterization of these processes and products. Phil holds a Ph.D. in Biochemical Eng. from Birmingham University and followed this with post-doctoral studies at Cambridge University.